BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1115 related articles for article (PubMed ID: 34001125)

  • 21. Age alone is not a barrier to efficacy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: analysis of 1138 patients from the UK and Ireland Colorectal Peritoneal Metastases Registry.
    Kelly ME; O'Sullivan NJ; Bolger JC; Polignano F; Youssef H; Renehan A; Malcomson L; Alves S; Cecil T; Mulsow J; Moran B; Mohamed F;
    Br J Cancer; 2023 Jan; 128(1):42-47. PubMed ID: 36347966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO
    Rotolo S; Di Giorgio A; Santullo F; Attalla El Halabieh M; Lodoli C; Abatini C; Pacelli F
    Updates Surg; 2021 Aug; 73(4):1443-1448. PubMed ID: 33782856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases.
    Ljunggren M; Nordenvall C; Palmer G
    Eur J Surg Oncol; 2021 Nov; 47(11):2865-2872. PubMed ID: 34116900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective analysis.
    Repullo DJ; Barbois S; Leonard D; Bohlok A; Van den Audenaeren ET; Hendlisz A; Van den Eynde M; Donckier V; Kartheuser A; Liberale G
    Eur J Surg Oncol; 2021 Jul; 47(7):1661-1667. PubMed ID: 33602530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for small bowel neuroendocrine tumors with peritoneal metastasis.
    Hajjar R; Mercier F; Passot G; Pasquer A; Gelli M; Levine EA; Villeneuve L; Poncet G; Walter T; Glehen O
    Eur J Surg Oncol; 2022 Jul; 48(7):1626-1630. PubMed ID: 35418324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcomes of elderly patients with peritoneal metastases of colorectal origin after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Weksler Y; Hoffman A; Green E; Kyzer M; Nevo N; Gerstenhaber F; Greenberg R; Klausner JM; Gutman M; Lahat G; Berger Y; Geva R; Nizri E
    Surg Oncol; 2022 Sep; 44():101848. PubMed ID: 36126349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of the learning curve of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on the treatment of colorectal peritoneal metastasis.
    Chidambarasamy ES; Chia CS; Johnny Ong CA; Soo KC; Ching Teo MC; Ching Tan GH
    Asian J Surg; 2022 Jan; 45(1):339-345. PubMed ID: 34148748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastric cancer with peritoneal metastases: a single center outline and comparison of different surgical and intraperitoneal treatments.
    Santullo F; Ferracci F; Abatini C; Halabieh MAE; Lodoli C; D'Annibale G; Di Cesare L; D'Agostino L; Pecere S; Di Giorgio A; Strippoli A; Pacelli F
    Langenbecks Arch Surg; 2023 Nov; 408(1):437. PubMed ID: 37973620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with improved perioperative outcomes: a single-center early experience propensity-matched analysis.
    Shaltiel T; Solomon D; Pletcher ER; Golas BJ; Magge DR; Sarpel U; Labow DM; Cohen NA
    Surg Endosc; 2022 Aug; 36(8):6153-6161. PubMed ID: 35080674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Complete cytoreductive surgery is the key to improving survival of colorectal cancer patients with peritoneal metastases: comment on PROPHYLOCHIP and PRODIGE 7].
    An SL; Cai J; Wang H; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):220-224. PubMed ID: 34645165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: a 13 years-retrospective monocentric study.
    Livin M; Leonard D; Bachmann R; Remue C; Barbois S; Cotte E; Van Den Eynde M; De Cuyper A; Sinapi I; Van Maanen A; Kartheuser A
    Acta Gastroenterol Belg; 2022; 85(4):573-579. PubMed ID: 36566366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A total neoadjuvant chemotherapy approach is associated with improved recurrence-free survival in patients with colorectal peritoneal metastases undergoing cytoreductive surgery and HIPEC.
    Hanna DN; Macfie R; Ghani MO; Hermina A; Mina A; Cha DE; Bailey CE; Cohen N; Labow D; Golas B; Sarpel U; Magge D; Idrees K
    J Surg Oncol; 2023 Mar; 127(3):442-449. PubMed ID: 36350108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal adenocarcinoma.
    Flood MP; Roberts G; Mitchell C; Ramsay R; Michael M; Heriot AG; Kong JC
    Asia Pac J Clin Oncol; 2024 Feb; 20(1):32-40. PubMed ID: 36880398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postoperative oxaliplatin-based hyperthermic intraperitoneal chemotherapy: an effective and safe palliative treatment option for colorectal cancer with peritoneal metastasis.
    Sun T; Li K; Xu G; Zhu K; Wang Q; Dang C; Yuan D
    World J Surg Oncol; 2021 Jul; 19(1):200. PubMed ID: 34229721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study.
    Leimkühler M; Hemmer PHJ; Reyners AKL; de Groot DJA; van Ginkel RJ; Been LB; de Bock GH; van Leeuwen BL
    World J Surg Oncol; 2019 Jan; 17(1):14. PubMed ID: 30635070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery.
    Mangieri CW; Moaven O; Valenzuela CD; Erali RA; Votanopoulos KI; Shen P; Levine EA
    J Surg Oncol; 2022 Mar; 125(4):703-711. PubMed ID: 34841542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncological impact of intraperitoneal chemotherapy after cytoreductive surgery for patients with colorectal peritoneal metastasis: A bi-institutional retrospective analysis.
    Park SY; Park JS; Kim HJ; Kim JG; Kang BW; Baek JH; Kim HR; Kim CH; Kim YJ; Choi GS
    J Surg Oncol; 2023 Mar; 127(4):668-677. PubMed ID: 36515216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
    Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D
    Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and Molecular Features in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Colorectal Cancer.
    Di Giorgio A; Santullo F; Attalla El Halabieh M; Lodoli C; Abatini C; Calegari MA; Martini M; Rotolo S; Pacelli F
    J Gastrointest Surg; 2021 Oct; 25(10):2649-2659. PubMed ID: 34244953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.